Summary

Paroxysmal Nocturnal Hemoglobinuria Market – Scope of Report
TMR’s report on the global paroxysmal nocturnal hemoglobinuria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paroxysmal nocturnal hemoglobinuria market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paroxysmal nocturnal hemoglobinuria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the paroxysmal nocturnal hemoglobinuria market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paroxysmal nocturnal hemoglobinuria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paroxysmal nocturnal hemoglobinuria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paroxysmal nocturnal hemoglobinuria market.

The report delves into the competitive landscape of the global paroxysmal nocturnal hemoglobinuria market. Key players operating in the global paroxysmal nocturnal hemoglobinuria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paroxysmal nocturnal hemoglobinuria market profiled in this report.

Key Questions Answered in Global paroxysmal nocturnal hemoglobinuria Market Report
• What is the sales/revenue generated by paroxysmal nocturnal hemoglobinuria across all regions during the forecast period?
• What are the opportunities in the global paroxysmal nocturnal hemoglobinuria market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Paroxysmal Nocturnal Hemoglobinuria Market – Research Objectives and Research Approach
The comprehensive report on the global paroxysmal nocturnal hemoglobinuria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global paroxysmal nocturnal hemoglobinuria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paroxysmal nocturnal hemoglobinuria market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment, 2020-2034
        6.3.1. Medication
            6.3.1.1. Eculizumab
            6.3.1.2. Ravulizumab
        6.3.2. Supplements
        6.3.3. Blood Transfusion
        6.3.4. Bone Marrow Transplant
        6.3.5. Immunosuppressive Therapy
    6.4. Market Attractiveness Analysis, by Treatment
7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by End-user, 2020-2034
        7.3.1. Hospitals & Clinics
        7.3.2. Homecare Settings
        7.3.3. Others (Research Institutes, etc.)
    7.4. Market Attractiveness Analysis, by End-user
8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2020-2034
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
    9.1. Introduction
    9.2. Key Findings
    9.3. Market Value Forecast, by Treatment, 2020-2034
        9.3.1. Medication
            9.3.1.1. Eculizumab
            9.3.1.2. Ravulizumab
        9.3.2. Supplements
        9.3.3. Blood Transfusion
        9.3.4. Bone Marrow Transplant
        9.3.5. Immunosuppressive Therapy
    9.4. Market Value Forecast, by End-user, 2020-2034
        9.4.1. Hospitals & Clinics
        9.4.2. Homecare Settings
        9.4.3. Others (Research Institutes, etc.)
    9.5. Market Value Forecast, by Country, 2020-2034
        9.5.1. U.S.
        9.5.2. Canada
    9.6. Market Attractiveness Analysis
        9.6.1. By Treatment
        9.6.2. By End-user
        9.6.3. By Country
10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Treatment, 2020-2034
        10.3.1. Medication
            10.3.1.1. Eculizumab
            10.3.1.2. Ravulizumab
        10.3.2. Supplements
        10.3.3. Blood Transfusion
        10.3.4. Bone Marrow Transplant
        10.3.5. Immunosuppressive Therapy
    10.4. Market Value Forecast, by End-user, 2020-2034
        10.4.1. Hospitals & Clinics
        10.4.2. Homecare Settings
        10.4.3. Others (Research Institutes, etc.)
    10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        10.5.1. Germany
        10.5.2. U.K.
        10.5.3. France
        10.5.4. Italy
        10.5.5. Spain
        10.5.6. Rest of Europe
    10.6. Market Attractiveness Analysis
        10.6.1. By Treatment
        10.6.2. By End-user
        10.6.3. By Country/Sub-region
11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Treatment, 2020-2034
        11.3.1. Medication
            11.3.1.1. Eculizumab
            11.3.1.2. Ravulizumab
        11.3.2. Supplements
        11.3.3. Blood Transfusion
        11.3.4. Bone Marrow Transplant
        11.3.5. Immunosuppressive Therapy
    11.4. Market Value Forecast, by End-user, 2020-2034
        11.4.1. Hospitals & Clinics
        11.4.2. Homecare Settings
        11.4.3. Others (Research Institutes, etc.)
    11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.5.1. China
        11.5.2. Japan
        11.5.3. India
        11.5.4. Australia & New Zealand
        11.5.5. Rest of Asia Pacific
    11.6. Market Attractiveness Analysis
        11.6.1. By Treatment
        11.6.2. By End-user
        11.6.3. By Country/Sub-region
12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Treatment, 2020-2034
        12.3.1. Medication
            12.3.1.1. Eculizumab
            12.3.1.2. Ravulizumab
        12.3.2. Supplements
        12.3.3. Blood Transfusion
        12.3.4. Bone Marrow Transplant
        12.3.5. Immunosuppressive Therapy
    12.4. Market Value Forecast, by End-user, 2020-2034
        12.4.1. Hospitals & Clinics
        12.4.2. Homecare Settings
        12.4.3. Others (Research Institutes, etc.)
    12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.5.1. Brazil
        12.5.2. Mexico
        12.5.3. Rest of Latin America
    12.6. Market Attractiveness Analysis
        12.6.1. By Treatment
        12.6.2. By End-user
        12.6.3. By Country/Sub-region
13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Treatment, 2020-2034
        13.3.1. Medication
            13.3.1.1. Eculizumab
            13.3.1.2. Ravulizumab
        13.3.2. Supplements
        13.3.3. Blood Transfusion
        13.3.4. Bone Marrow Transplant
        13.3.5. Immunosuppressive Therapy
    13.4. Market Value Forecast, by End-user, 2020-2034
        13.4.1. Hospitals & Clinics
        13.4.2. Homecare Settings
        13.4.3. Others (Research Institutes, etc.)
    13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.5.1. GCC Countries
        13.5.2. South Africa
        13.5.3. Rest of Middle East & Africa
    13.6. Market Attractiveness Analysis
        13.6.1. By Treatment
        13.6.2. By End-user
        13.6.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2023)
    14.3. Company Profiles
        14.3.1. Alexion Pharmaceuticals, Inc.
            14.3.1.1. Company Overview
            14.3.1.2. Product Portfolio
            14.3.1.3. SWOT Analysis
            14.3.1.4. Financial Overview
            14.3.1.5. Strategic Overview
        14.3.2. Apellis Pharmaceuticals
            14.3.2.1. Company Overview
            14.3.2.2. Product Portfolio
            14.3.2.3. SWOT Analysis
            14.3.2.4. Financial Overview
            14.3.2.5. Strategic Overview
        14.3.3. Genentec, Inc.
            14.3.3.1. Company Overview
            14.3.3.2. Product Portfolio
            14.3.3.3. SWOT Analysis
            14.3.3.4. Financial Overview
            14.3.3.5. Strategic Overview
        14.3.4. Novartis AG
            14.3.4.1. Company Overview
            14.3.4.2. Product Portfolio
            14.3.4.3. SWOT Analysis
            14.3.4.4. Financial Overview
            14.3.4.5. Strategic Overview
        14.3.5. The Takeda Pharmaceutical Company Limited
            14.3.5.1. Company Overview
            14.3.5.2. Product Portfolio
            14.3.5.3. SWOT Analysis
            14.3.5.4. Financial Overview
            14.3.5.5. Strategic Overview
        14.3.6. Kira Pharmaceuticals
            14.3.6.1. Company Overview
            14.3.6.2. Product Portfolio
            14.3.6.3. SWOT Analysis
            14.3.6.4. Financial Overview
            14.3.6.5. Strategic Overview
        14.3.7. F. Hoffman-La Roche AG
            14.3.7.1. Company Overview
            14.3.7.2. Product Portfolio
            14.3.7.3. SWOT Analysis
            14.3.7.4. Financial Overview
            14.3.7.5. Strategic Overview
        14.3.8. Akari Therapeutics PLC
            14.3.8.1. Company Overview
            14.3.8.2. Product Portfolio
            14.3.8.3. SWOT Analysis
            14.3.8.4. Financial Overview
            14.3.8.5. Strategic Overview
        14.3.9. Omeros Corporation
            14.3.9.1. Company Overview
            14.3.9.2. Product Portfolio
            14.3.9.3. SWOT Analysis
            14.3.9.4. Financial Overview
            14.3.9.5. Strategic Overview
        14.3.10. Regeneron Pharmaceuticals, Inc.
            14.3.10.1. Company Overview
            14.3.10.2. Product Portfolio
            14.3.10.3. SWOT Analysis
            14.3.10.4. Financial Overview
            14.3.10.5. Strategic Overview